The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy

Chun Te Wu, Wen Cheng Chen, Shuen Kuei Liao, Cheng Lung Hsu, Kuan Der Lee, Miao Fen Chen*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

26 Scopus citations

Abstract

Hormone therapy for prostate cancer eventually fails leading to a stage called hormone-resistant (HR) disease. To investigate the issue about the characteristics and the radiation response in HR prostate cancer, we established HR cell sub-lines, 22RV1-F and 22RV1-DF, from 22RV1 cells with androgen deprivation for 16 weeks, and obtained LNCaP-HR from LNCaP with long-term bicalutamide treatment. We examined their sensitivities to radiation therapy and the underlying mechanisms. In vitro and in vivo faster tumor growth rate was noted in the HR prostate cancer cells when compared with control. Moreover, HR prostate cancer cells had greater capacity to scavenge reactive oxygen species, and suffered less apoptosis and senescence, and subsequently were more likely to survive from irradiation as measured by clonogenic assay in vitroana growth delay in vivo. The decreased p53 and increased mouse double minute 2 oncogene (MDM2) might be the potential underlying mechanisms for the more aggressive growth and more radioresistance in H R prostate cancer cells. In conclusion, HR prostate cancer cells appeared to be more aggressive in tumor growth and in resistance to radiation treatment. Regulation of the expressions of p53 and MDM2 should be the promising treatment strategies for relative radioresistant prostate cancer.

Original languageEnglish
Pages (from-to)633-643
Number of pages11
JournalEndocrine-Related Cancer
Volume14
Issue number3
DOIs
StatePublished - 09 2007

Fingerprint

Dive into the research topics of 'The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy'. Together they form a unique fingerprint.

Cite this